PURPOSE: The aim of this retrospective study was to compare the outcome of frozen-thawed blastocysts derived from the cycles using controlled ovarian stimulation with GnRH agonists vs. GnRH antagonists. METHODS: Survival, pregnancy and cumulative live birth rates in 231 freeze-thaw cycles derived from the GnRH agonist cycles (GnRH agonist group), and in 175 freeze-thaw cycles derived from the GnRH antagonist cycles (GnRH antagonist group) were compared. RESULTS: In the GnRH agonist group significantly higher proportion of blastocysts survived the thawing procedure than in the GnRH antagonist group (86.1% versus 78.5%; p < 0.01). The differences in cumulative live birth rates did not differ significantly between the groups: in the GnRH agonist group the cumulative live birth rate was 16.5%, and in the GnRH antagonist group it was 14.2%. CONCLUSIONS: Frozen-thawed blastocysts derived from the GnRH agonist cycles have better survival rates and similar cumulative live birth rates than those derived from the GnRH antagonist cycles.
PURPOSE: The aim of this retrospective study was to compare the outcome of frozen-thawed blastocysts derived from the cycles using controlled ovarian stimulation with GnRH agonists vs. GnRH antagonists. METHODS: Survival, pregnancy and cumulative live birth rates in 231 freeze-thaw cycles derived from the GnRH agonist cycles (GnRH agonist group), and in 175 freeze-thaw cycles derived from the GnRH antagonist cycles (GnRH antagonist group) were compared. RESULTS: In the GnRH agonist group significantly higher proportion of blastocysts survived the thawing procedure than in the GnRH antagonist group (86.1% versus 78.5%; p < 0.01). The differences in cumulative live birth rates did not differ significantly between the groups: in the GnRH agonist group the cumulative live birth rate was 16.5%, and in the GnRH antagonist group it was 14.2%. CONCLUSIONS: Frozen-thawed blastocysts derived from the GnRH agonist cycles have better survival rates and similar cumulative live birth rates than those derived from the GnRH antagonist cycles.
Authors: M Fluker; J Grifo; A Leader; M Levy; D Meldrum; S J Muasher; J Rinehart; Z Rosenwaks; R T Scott; W Schoolcraft; D B Shapiro Journal: Fertil Steril Date: 2001-01 Impact factor: 7.329
Authors: N Nikolettos; S Al-Hasani; R Felberbaum; L C Demirel; H Riethmüller-Winzen; T Reissmann; B Schöpper; R Sturm; K Diedrich Journal: Eur J Obstet Gynecol Reprod Biol Date: 2000-11 Impact factor: 2.435
Authors: S Kol; A Lightman; T Hillensjo; P Devroey; B Fauser; B Tarlatzis; B Mannaerts; J Itskovitz-Eldor Journal: Hum Reprod Date: 1999-09 Impact factor: 6.918
Authors: Anna Sophie Seelig; Safa Al-Hasani; Alexander Katalinic; Beate Schöpper; Rita Sturm; Klaus Diedrich; Michael Ludwig Journal: Fertil Steril Date: 2002-03 Impact factor: 7.329